Serum concentration of sCD30 and risk of NHL: results for overall study and stratifying by years from blood collection to case diagnosis
| sCD30 concentration, ng/mL* . | Overall . | Years from blood collection to case diagnosis . | ||||||
|---|---|---|---|---|---|---|---|---|
| 1-2 . | 3-5 . | 6-10 . | ||||||
| NCo/NCa . | OR (95% CI) . | NCo/NCa . | OR (95% CI) . | NCo/NCa . | OR (95% CI) . | NCo/NCa . | OR (95% CI) . | |
| Less than or equal to 8.8 | 59/33 | 1.0 | 15/11 | 1.0 | 21/10 | 1.0 | 23/12 | 1.0 |
| 8.9-13.4 | 58/42 | 1.4 (0.8-2.6) | 17/9 | 0.9 (0.2-3.3) | 14/12 | 2.4 (0.7-7.9) | 27/21 | 1.3 (0.5-3.2) |
| 13.5-20.6 | 59/59 | 2.2 (1.2-4.1) | 15/13 | 1.5 (0.4-5.5) | 27/23 | 2.4 (0.8-7.4) | 17/23 | 2.7 (1.0-7.1) |
| More than 20.6 | 58/100 | 4.1 (2.2-7.8) | 15/29 | 3.8 (1.0-13.8) | 17/34 | 7.0 (2.0-23.9) | 26/37 | 3.0 (1.2-7.5) |
| PTrend | < .001 | .009 | .002 | .01 | ||||
| sCD30 concentration, ng/mL* . | Overall . | Years from blood collection to case diagnosis . | ||||||
|---|---|---|---|---|---|---|---|---|
| 1-2 . | 3-5 . | 6-10 . | ||||||
| NCo/NCa . | OR (95% CI) . | NCo/NCa . | OR (95% CI) . | NCo/NCa . | OR (95% CI) . | NCo/NCa . | OR (95% CI) . | |
| Less than or equal to 8.8 | 59/33 | 1.0 | 15/11 | 1.0 | 21/10 | 1.0 | 23/12 | 1.0 |
| 8.9-13.4 | 58/42 | 1.4 (0.8-2.6) | 17/9 | 0.9 (0.2-3.3) | 14/12 | 2.4 (0.7-7.9) | 27/21 | 1.3 (0.5-3.2) |
| 13.5-20.6 | 59/59 | 2.2 (1.2-4.1) | 15/13 | 1.5 (0.4-5.5) | 27/23 | 2.4 (0.8-7.4) | 17/23 | 2.7 (1.0-7.1) |
| More than 20.6 | 58/100 | 4.1 (2.2-7.8) | 15/29 | 3.8 (1.0-13.8) | 17/34 | 7.0 (2.0-23.9) | 26/37 | 3.0 (1.2-7.5) |
| PTrend | < .001 | .009 | .002 | .01 | ||||
Odds ratios computed using conditional logistic regression.
NCo indicates number of controls; and NCa, number of cases.
sCD30 concentration categorized using control quartiles as cut-points.